It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. ...

AbbVie (NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currently high yield and strong cash flow, AbbVie could provide dividend lovers with reliable income for years to come. AbbVie's yield is attractive The S&P 500 index has a paltry yield of 1.1% today. The average pharmaceutical company, using iShares U.S. Pharmaceuticals ETF a ...

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationNORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at [investors.abbvie.com]. An archived edition of the sess ...

Investment Plans - AbbVie has announced a $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois, integrating advanced manufacturing technologies and AI for obesity and next-generation neuroscience medications [1][2] - Construction is set to begin in spring 2026, with both facilities expected to be operational by 2029 [1] Employment and Capacity Expansion - The company plans to hire 300 employees in North Chicago, including manufacturing operators, scientists, lab technicians, and engineers to support the expanded operations [2] - AbbVie has been increasing its API manufacturing capacity in the US over the past six months [2] Relocation of Production - In September 2025, AbbVie initiated the first phase of this investment by breaking ground on a chemical synthesis facility aimed at relocating API production for certain neuroscience, immunology, and oncology products from Europe and Asia back to the US [3] Additional Investments - AbbVie has also revealed plans for a device manufacturing facility acquisition in Arizona and significant investments at its Massachusetts site, with further investments in other US states expected to be announced in 2026 [4] - The chairman and CEO stated that this milestone reflects progress towards a $100 billion commitment to US R&D and capital investments over the next decade [4] Strategic Acquisitions - In August 2025, AbbVie signed an agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2 billion, which includes upfront payments and development milestones [5]

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to traditional chemoimmunotherapy. By combining two classes of oral medications, the treatment offers patients the potential for periods ...

格隆汇2月24日｜艾伯维表示，将投资3.8亿美元在美国伊利诺伊州园区建造两座新的活性药物成分生产 设施，以扩大其神经科学和减肥药物的国内生产能力。 公司在美国已经拥有11个生产基地，并且正在 与美国多个州就潜在项目进行磋商，预计将于今年宣布进一步投资。 ...

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its... ...

therapeutic effects. Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the U.S. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology and oncology products from Europe and Asia to the U.S.With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., ...

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

Core Insights - Dividend stocks and Consumer Staples experienced losses or flat prices last week, with Crown Castle and AbbVie among the biggest decliners, while Coca-Cola outperformed due to positive Wall Street research notes [1] Group 1: Company Performance - Crown Castle (CCI) saw a significant decline after terminating its agreement with DISH Wireless due to a default on payment obligations, leading to a potential $3.5 billion revenue shortfall and an expected net loss of $780 million in 2026 [1] - AbbVie (ABBV) dropped nearly 3% despite FDA approvals for its drug, facing headwinds from broader healthcare sector weakness and drug pricing policy uncertainties [1] - AT&T (T) fell approximately 2.5% after two banks lowered their price targets, reflecting concerns about the competitive telecom environment, particularly with T-Mobile's new service [1] Group 2: Dividend Changes - Crown Castle reduced its quarterly dividend from $1.565 to $1.0625 per share, raising questions about the sustainability of its dividend amid financial challenges [1] - AbbVie has increased its dividend for 13 consecutive years, with the latest quarterly dividend at $1.73 per share, reflecting a 5.5% increase from the previous rate [1] - AT&T maintains a quarterly dividend of $0.2775 per share, yielding close to 4% at current prices, but faces limited near-term upside according to analyst consensus [1] Group 3: Market Trends - The Schwab U.S. Dividend Equity ETF was flat, while the Consumer Staples SPDR fell by 1.8%, indicating a pause in the performance of dividend stocks [1] - The VIX index is at 20.23, indicating a boundary between normal and elevated uncertainty, while the 10-year Treasury yield is at 4.08%, down from 4.29%, providing some relief for rate-sensitive dividend stocks [2] - Overall, 2026 has been a strong year for dividend stocks, with investors seeking stability amid market volatility [2]